NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 107 filers reported holding NGM BIOPHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.00 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $74,838 | -75.5% | 28,895 | -61.3% | 0.01% | -75.6% |
| Q1 2023 | $304,849 | -41.8% | 74,718 | -28.4% | 0.04% | -51.8% |
| Q4 2022 | $524,003 | +17.0% | 104,383 | +204.6% | 0.08% | +25.0% |
| Q3 2022 | $448,000 | -23.0% | 34,267 | -10.2% | 0.07% | +36.0% |
| Q1 2022 | $582,000 | -42.9% | 38,179 | -33.7% | 0.05% | -35.9% |
| Q4 2021 | $1,019,000 | -10.6% | 57,546 | +6.1% | 0.08% | -4.9% |
| Q3 2021 | $1,140,000 | +59.7% | 54,246 | +49.9% | 0.08% | +74.5% |
| Q2 2021 | $714,000 | +340.7% | 36,200 | +175.3% | 0.05% | +261.5% |
| Q1 2020 | $162,000 | – | 13,150 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Greenspring Associates, LLC | 1,573,357 | $47,665,000 | 61.89% |
| RHO CAPITAL PARTNERS INC | 3,766,666 | $114,111,000 | 60.06% |
| Column Group LLC | 15,396,116 | $466,502,000 | 42.31% |
| Ponoi II Management, LLC | 1,298,908 | $39,357,000 | 28.68% |
| Ponoi Management, LLC | 1,298,908 | $39,357,000 | 22.52% |
| Euclidean Capital LLC | 2,083,602 | $63,133,000 | 13.36% |
| Aquilo Capital Management, LLC | 1,005,534 | $30,463,000 | 6.33% |
| Octagon Capital Advisors LP | 75,227 | $2,279,000 | 0.79% |
| Jasper Ridge Partners, L.P. | 308,750 | $9,354,000 | 0.41% |
| Point72 Asset Management, L.P. | 1,761,157 | $53,354,000 | 0.26% |